BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35804954)

  • 41. On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016).
    Barbieri PG; Mirabelli D; Magnani C; Brollo A
    Tumori; 2019 Aug; 105(4):304-311. PubMed ID: 29714657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
    Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
    J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiplex Soluble Biomarker Analysis from Pleural Effusion.
    Javadi J; Dobra K; Hjerpe A
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia-Pacific Region.
    Ke H; Kao S; Lee K; Takahashi K; Goh HP; Linton A
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):177-190. PubMed ID: 34161674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Environmentally-induced malignant pleural mesothelioma and HLA distribution in Turkey.
    Karakoca Y; Emri S; Bagci T; Demir A; Erdem Y; Baris E; Sahin AA
    Int J Tuberc Lung Dis; 1998 Dec; 2(12):1017-22. PubMed ID: 9869119
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey.
    Senyiğit A; Babayiğit C; Gökirmak M; Topçu F; Asan E; Coşkunsel M; Işik R; Ertem M
    Respiration; 2000; 67(6):610-4. PubMed ID: 11124642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
    Bruno R; Alì G; Fontanini G
    J Thorac Dis; 2018 Jan; 10(Suppl 2):S342-S352. PubMed ID: 29507804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
    Liu H; Wu L; Ji K; Wang W
    Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
    Crovella S; Bianco AM; Vuch J; Zupin L; Moura RR; Trevisan E; Schneider M; Brollo A; Nicastro EM; Cosenzi A; Zabucchi G; Borelli V
    J Toxicol Environ Health A; 2016; 79(3):129-41. PubMed ID: 26818092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CT findings in malignant pleural mesothelioma related to nonoccupational exposure to asbestos and fibrous zeolite (erionite).
    Erzen C; Eryilmaz M; Kalyoncu F; Bilir N; Sahin A; Baris YI
    J Comput Assist Tomogr; 1991; 15(2):256-60. PubMed ID: 1848247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
    Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
    J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
    Aguilar-Madrid G; Pesch B; Calderón-Aranda ES; Burek K; Jiménez-Ramírez C; Juárez-Pérez CA; Ochoa-Vázquez MD; Torre-Bouscoulet L; Acosta-Saavedra LC; Sada-Ovalle I; García-Figueroa J; Alvarado-Cabrero I; Castillo-González P; Báez-Saldaña AR; Pérez-Padilla JR; Osnaya-Juárez J; Rivera-Rosales RM; García-Bazán EM; Bautista-Aragón YL; Lazcano-Hernandez E; Munguía-Canales DA; Argote-Greene LM; Taeger D; Weber DG; Casjens S; Raiko I; Brüning T; Johnen G
    Int J Med Sci; 2018; 15(9):883-891. PubMed ID: 30008600
    [No Abstract]   [Full Text] [Related]  

  • 55. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
    Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
    Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
    Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
    Amati M; Tomasetti M; Scartozzi M; Mariotti L; Ciuccarelli M; Valentino M; Governa M; Santarelli L
    G Ital Med Lav Ergon; 2007; 29(3 Suppl):335-8. PubMed ID: 18409713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
    Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
    Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
    Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
    Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.
    Kokturk N; Firat P; Akay H; Kadilar C; Ozturk C; Zorlu F; Gungen Y; Emri S
    Lung Cancer; 2005 Nov; 50(2):189-98. PubMed ID: 16043260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.